Apheresis to Obtain Plasma and White Blood Cells in Malies
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01511601|
Recruitment Status : Withdrawn
First Posted : January 18, 2012
Last Update Posted : January 15, 2019
- Some clinical trials require larger amounts of plasma and white blood cells than can be collected through simple blood donations. Apheresis is a procedure used to collect parts of the blood for study and return the rest of the blood to the donor. Healthy volunteers who provide plasma and white blood cells for study may need to give multiple donations. Researchers want to use apheresis to collect plasma and white blood cells from healthy volunteers in Mali.
- To collect plasma and white blood cells from healthy volunteers in Mali.
- Healthy volunteers between 18 and 55 years of age.
- Volunteers must be in National Institute of Allergy and Infectious Diseases clinical trials.
- Participants will be screened with a physical exam and medical history. They will also provide basic blood and urine samples.
- Participants will have apheresis to collect plasma and white blood cells for study. Before each collection, they will provide a small blood sample for testing. They will be monitored during and after donation to prevent side effects.
- Under this protocol, participants may have apheresis up to six times per year.
- No treatment will be provided as part of this protocol.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Apheresis to Obtain Plasma and Leukocytes in Mali for In Vitro Studies|
|Study Start Date :||December 20, 2011|
|Study Completion Date :||July 28, 2016|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01511601
|Principal Investigator:||Peter D Crompton, M.D.||National Institute of Allergy and Infectious Diseases (NIAID)|